| 产品介绍 |
Alisertib (MLN8237)是Aurora A选择性抑制剂，IC50为1.2 nM，比对Aurora B的抑制性高200倍。 |
| 备注 |
Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3. |
| 生化机理 |
Alisertib is a selective Aurora kinase A inhibitor with a median IC50 of 61 nM. Alisertib is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the Aurora A kinase (serine/threonine protein kinase) with potential antineoplastic activity. |
| 别名 |
MLN 8237; MLN8237；MLN-8237;4-((9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并(5,4-d)(2)苯并氮杂卓-2-基)氨基)-2-甲氧基苯甲酸;;MLN 8237; MLN8237；MLN-8237; 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido(5,4-d)(2)benzazepin-2-yl)amino)-2-methoxybenzoic acid; |
